Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

HALO STOCK ANALYSIS

Halozyme Therapeutics Inc — price, returns and risk statistics

HALOHalozyme Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Price summary

Last Close

81.57 $

Jul 7, 26

Market Cap

10 B $

Q1 2026 (TTM)

52-Week Range

54.22 $81.57 $

Return and risk cards

Total Return

%+50.4

Trailing 1-year performance

Volatility

%30.7

Price fluctuation measure

Sharpe Ratio

0.19

Risk/Return ratio

Sortino Ratio

0.19

Downside risk/return

Distance to Peak

%0.0

Difference from 52-week peak

Maximum Drawdown

-%24.1

Deepest 1-year decline

Seasonality

Seasonality Chart

Year 2023
Year 2024
Year 2025
Current Period 2026
3/3 positive months

Periodic Returns

1M

+14.0%

3M

+28.3%

6M

+11.5%

YTD

+21.2%

1Y

+50.4%

3Y

+122.7%

Returns are computed from split-adjusted closes; dividends are not included.

YTD Return — Stock vs Asset Classes

Year-to-date
HALO+21.2%Gold-4.4%Silver-12.9%S&P 500+10.1%

Stock and gold/silver returns are in USD (metals converted into the stock's currency). The S&P 500 index is measured in its own currency.

Monthly positivity

Monthly Avg Positive/Negative Close

Positive Count
Negative Count
Average Positive %
Average Negative %

Frequently Asked Questions

What is the current Halozyme Therapeutics Inc (HALO) stock price?

HALO last closed at 81.57 $ (Jul 7, 26). Price data is refreshed after every trading day.

What is the P/E ratio of HALO?

Halozyme Therapeutics Inc trades at a trailing-twelve-month P/E of 28.73. See the comparison tables on the Peers tab for the industry context.

What is the market capitalization of Halozyme Therapeutics Inc?

Halozyme Therapeutics Inc (HALO) has a market capitalization of approximately 10 B $ as of the latest reported period.

Who are the main competitors of HALO?

Key peers of Halozyme Therapeutics Inc include CSL Ltd, TELIX Pharmaceuticals Ltd, Mesoblast Ltd. A detailed metric comparison is available on the Peers tab.

Go deeper on HALO

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.